Vergent Bioscience
Manufacturing · Minnesota, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5810 W 78th St Ste 222, Minneapolis, Min...Phone Number
(952) 479-7496Website
www.vergentbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Vergent Bioscience
Vergent Bioscience is a clinical-stage biotechnology company focused on enhancing cancer surgery through its lead compound, VGT-309, a tumor-targeted fluorescent imaging agent. This innovative technology enables surgeons to visualize previously undetected tumors in real-time during surgery, ensuring complete removal of solid tumor tissue. The company aims to improve the accessibility and effectiveness of minimally invasive and robotic-assisted cancer surgeries. Vergent is committed to transforming cancer care by optimizing surgical outcomes for patients with solid tumors.Explore more
Vergent Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vergent Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Vergent Bioscience has recently received funding, and reach out quickly before it becomes old news!
Vergent Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Vergent Bioscience has new funding data
Check out if Vergent Bioscience is spiking on competitors!
Earning: See what the market has to say on Vergent Bioscience recently announced quarterly report
Product Launch: Get notified when Vergent Bioscience launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Vergent Bioscience
Click to see if Vergent Bioscience had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Vergent Bioscience as Masked Content
Find 2 more new buyers
Compare Similar Companies to Vergent Bioscience
Compare insights from companies similar to Vergent Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vergent Bioscience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vergent Bioscience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vergent Bioscience.
Vergent Bioscience financials insights
Gather financial insights about Vergent Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$8.7M
2022
Series B
$21.5M
2025
Private Equity
$18.7M
Vergent Bioscience Tech Stack
A closer look at the technologies used by Vergent Bioscience
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Event
Events
Event
Events
Funding
Vergent Bioscience News & Media
Vergent Bioscience to Present Data on Abenacianine for Injection (VGT-309) at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that an abstract on abenacianine for injection (VGT-309) will be featured at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. The poster will highlight data from the Phase 2B, multicenter VISUALIZE study (NCT06145048) evaluating the safety and efficacy of abenacianine in patients undergoing surgeryVergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the company’s novel, investigational tumor-targeted fluorescent imaging agent, abenacianine for injection (VGT-309), as an adjunct for the intraoperative visualization of primary lung cancer, other pulmonary lesions, cancer containing lymph nodes, and positive surgicaVergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company’s Phase 2, multi-center VISUALIZE trial, evaluating the efficacy and safety of abenacianine for injection (VGT-309) in patients with cancer in the lung. Abenacianine for injection is a novel, investigational tumor-targeted fluorescent imaging agent designed to improve the visibility of difficult-to-find and pVergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that data published in The Annals of Thoracic Surgery reinforce the clinical potential of VGT-309, the company’s investigational intraoperative molecular imaging (IMI) agent, to help surgeons see difficult-to-find and previously undetected tumors in the lung during surgery. The findings support previous clinical trial results suggesting that VGT-309 could
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vergent Bioscience
Sign Up For FreeTo access detailed company insights
Vergent Bioscience is a clinical-stage biotechnology company focused on enhancing cancer surgery through its lead compound, VGT-309, a tumor-targeted fluorescent imaging agent. This innovative technology enables surgeons to visualize previously undetected tumors in real-time during surgery, ensuring complete removal of solid tumor tissue. The compa... Read More
